ephedrine sulfate injection
lifestar pharma llc - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none risk summary available data from randomized studies, case series, and reports of ephedrine sulfate use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. however, there are clinical considerations due to underlying conditions (see clinical considerations) . in animal reproduction studies, decreased fetal survival and fetal body weights were observed in the presence of maternal toxicity after normotensive pregnant rats were administered 60 mg/kg intravenous ephedrine sulfate (12 times the maximum recommended human dose (mrhd) of 50 mg/day). no malformations or embryofetal adverse effects were observed when pregnant rats or rabbits were treated with intravenous bolus doses of ephedrine sulfate during organogenesis at doses 1.9 and 7.7 times the mrhd, respectively [see data] . the estimate
theophylline tablet, extended release
teva pharmaceuticals, inc. - theophylline (unii: c137dtr5rg) (theophylline anhydrous - unii:0i55128jyk) - theophylline extended-release tablets are indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. theophylline extended-release tablets are contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product.
ephedrine injection
laboratory & allied ltd p.o box 42875-00100 nairobi - ephedrine hcl - injection - ephedrine hcl 30mg/ml - cardiac stimulants excluding cardiac glycosides:
ephedrine sulfate injection
xiromed, llc - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none risk summary available data from randomized studies, case series, and reports of ephedrine sulfate use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. however, there are clinical considerations due to underlying conditions (see clinical considerations) . in animal reproduction studies, decreased fetal survival and fetal body weights were observed in the presence of maternal toxicity after normotensive pregnant rats were administered 60 mg/kg intravenous ephedrine sulfate (12 times the maximum recommended human dose (mrhd) of 50 mg/day). no malformations or embryofetal adverse effects were observed when pregnant rats or rabbits were treated with intravenous bolus doses of ephedrine sulfate during organogenesis at doses 1.9 and 7.7 times the mrhd, respectively [see data ]. the estimated
ephedrine sulfate injection, solution
sagent pharmaceuticals - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none risk summary available data from randomized studies, case series, and reports of ephedrine sulfate use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. however, there are clinical considerations due to underlying conditions (see clinical considerations) . in animal reproduction studies, decreased fetal survival and fetal body weights were observed in the presence of maternal toxicity after normotensive pregnant rats were administered 60 mg/kg intravenous ephedrine sulfate (12 times the maximum recommended human dose (mrhd) of 50 mg/day). no malformations or embryo-fetal adverse effects were observed when pregnant rats or rabbits were treated with intravenous bolus doses of ephedrine sulfate during organogenesis at doses 1.9 and 7.7 times the mrhd, respectively [see data] . the estimate
ephedrine hydrochloride 30mg in 1ml solution for injection
martindale pharmaceuticals ltd - ephedrine hydrochloride - solution for injection - 30 milligram(s)/millilitre - ephedrine
elixophyllin - theophylline anhydrous liquid
caraco pharma, inc. - theophylline anhydrous (unii: 0i55128jyk) (theophylline anhydrous - unii:0i55128jyk) - theophylline anhydrous 80 mg in 15 ml - theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. elixophyllin elixir is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product.
ephedrine hcl sterop 10 mg/1 ml inj. sol. i.v./i.m./s.c. amp.
laboratoires sterop sa-nv - ephedrine hydrochloride 10 mg/ml - solution for injection - 10 mg/1 ml - ephedrine hydrochloride 10 mg/ml - adrenergic and dopaminergic agents; r03ca02 ephedrine
ephedrine hcl sterop 50 mg/1 ml inj. sol. i.v./i.m./s.c. amp.
laboratoires sterop sa-nv - ephedrine hydrochloride 50 mg/ml - solution for injection - 50 mg/1 ml - ephedrine hydrochloride 50 mg/ml - adrenergic and dopaminergic agents; r03ca02 ephedrine
ephedrine sulfate injection usp solution
auro pharma inc - ephedrine sulfate - solution - 50mg - ephedrine sulfate 50mg